Oxford Ups COVID-19 Testing Capacity With Thermo Fisher Deal

“The equipment further enhances Oxford’s capacity to quantify the response to vaccines accurately and on a large scale as part of our ongoing clinical trials of the Oxford coronavirus vaccine to assess vaccine performance,” the statement said.

Oxford is working on an experimental COVID-19 vaccine with AstraZeneca, and eagerly anticipated data from large studies of the vaccine, one of the frontrunners, is expected by year-end. Pfizer on Monday said its vaccine was over 90% effective.

Researchers at Oxford will expand the use of Thermo Fisher’s test in Britain’s COVID-19 infection survey by collecting and studying infection and antibody data for about a year, the chief investigator of the survey, Sarah Walker, said.

The test is called Thermo Scientific OmnipathTM Combi SARS-CoV-2 IgG ELISA, and the American company has also collaborated with WuXi Diagnostics and the Mayo Clinic on another COVID-19 test https://thermofisher.mediaroom.com/2020-05-13-Thermo-Fisher-Scientific-Response-to-COVID-19-Expands-to-Include-New-Serology-Test.

The Oxford statement said the collaboration would also help Britain in its plans to tackle the coronavirus. The country went into another lockdown this month following a surge in infections.

Disclaimer: This post has been auto-published from an agency feed without any modifications to the text and has not been reviewed by an editor